Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Mineralization (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Inc KANT

Healthcare Biotechnology
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (OTCPK:KANT)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders

PR Newswire December 19, 2024

$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - ML, HURA, KANT, VTS

Accesswire December 17, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders

PR Newswire December 16, 2024

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT

PR Newswire December 12, 2024

KANT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kineta, Inc. Is Fair to Shareholders

Business Wire December 12, 2024

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Accesswire December 12, 2024

Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)

GlobeNewswire November 8, 2024

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

GlobeNewswire October 8, 2024

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

GlobeNewswire October 4, 2024

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1

GlobeNewswire October 2, 2024

Kineta, Inc Transitioning from Nasdaq to OTC Markets

GlobeNewswire September 19, 2024

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

GlobeNewswire August 19, 2024

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

PR Newswire August 19, 2024

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

GlobeNewswire July 8, 2024

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

GlobeNewswire May 15, 2024

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

GlobeNewswire April 8, 2024

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 21, 2024

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

GlobeNewswire March 12, 2024

Kineta Announces Restructuring and Exploration of Strategic Alternatives

GlobeNewswire February 29, 2024

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

GlobeNewswire February 22, 2024